Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (March 21st Preview)
-
Measles resurgence: U.S. records sustained transmission after vaccination declines
U.S. public-health researchers report that measles has been continuously circulating nationwide for more than a year, with 1,300 confirmed infections already in 2026 and outbreaks spanning multiple states. The resurgence began with a protracted Texas outbreak in early 2025 and expanded to clusters on the Utah–Arizona border and in South Carolina. Brown University’s Pandemic Center and other public-health authorities link the return to falling MMR vaccination rates below the 95% herd-immunity threshold, and warn the U.S. may lose its historic elimination status. Health officials and the Pan American Health Organization are monitoring spread across states; 30 states reported cases in 2026 and 47 since 2025 began. Measles’ high transmissibility makes local pockets of undervaccination particularly risky—epidemiologists emphasize that even modest declines in coverage can sustain widespread transmission. The development raises operational concerns for outbreak preparedness and routine immunization programs in clinical and public-health settings. Note: Measles is highly contagious and requires >95% population immunity to interrupt sustained transmission.
-
ACIP upheaval – court injunction fuels claims of panel reshuffle
An outspoken member of the CDC’s Advisory Committee on Immunization Practices (ACIP) claimed the panel had been disbanded following a federal judge’s temporary injunction, then retracted the assertion hours later—sparking renewed scrutiny of the committee’s composition and recent votes. The episode follows Health Secretary Robert F. Kennedy Jr.’s dismissal of the prior 17 experts and appointment of a new ACIP whose members have been criticized by medical groups for lacking vaccine expertise. The injunction, issued after a lawsuit by the American Academy of Pediatrics and other medical organizations, found the new ACIP appointments procedurally improper and temporarily blocked the committee’s votes. The public retraction by ACIP vice-chair Robert Malone deepened confusion amid ongoing disputes over the committee’s vaccine guidance changes. Public-health stakeholders say the dispute threatens confidence in evidence-based immunization policy and could complicate CDC advisory processes. Clarification: ACIP advises the CDC on vaccine recommendations; court action centers on appointment procedures and procedural safeguards.
-
FDA demands sham-controlled trial for life‑prolonging Huntington’s gene therapy
The U.S. Food and Drug Administration told uniQure it expects a prospective, randomized, double-blind, sham-surgery–controlled study to support approval of AMT‑130, a one-time AAV-based gene therapy for Huntington’s disease, reversing earlier regulatory openness to external-control data. AMT‑130 showed a roughly 75% slowing of disease progression in Phase I/II trials, prompting optimism among patients and clinicians; the FDA’s Type A meeting position requires a controlled surgical comparator. The agency said Phase I/II external-control data are insufficient for primary evidence of effectiveness; uniQure must now plan a long-duration sham-controlled trial. Clinicians and patient advocates warn that a prolonged sham arm raises ethical and practical concerns because some participants might progress beyond eligibility while waiting for active treatment. The decision underscores rising regulatory expectations for randomized, blinded evidence in invasive neurotherapies and could delay access for seriously ill patients. Clarification: A sham surgery control gives placebo-like conditions for surgical trials and raises unique ethical considerations when tested therapies are potentially life‑extending.
-
Earendil raises $787M... AI-driven biologics startup scales toward clinic
AI-native biotech Earendil Labs secured $787 million in private funding to accelerate a large pipeline of biologics across autoimmune and oncology programs and to expand R&D operations in the U.S. and China. The round, led by Dimension and Luminous Ventures with Sanofi participation, funds multiple programs toward clinical testing and supports a potential Hong Kong IPO. CEO Jian Peng said the capital lets the company operate at a “fundamentally different scale.” Earendil is developing >40 programs—including bispecifics, T-cell engagers and antibody‑drug conjugates—focused on targets like DLL3 (lung cancer) and TL1A (IBD). The company’s strategy combines AI design with rapid experimental validation and has drawn repeat partnerships with Sanofi. Investors and industry watchers view the financing as a signal that large private financings for AI-driven biotech remain available for firms showing rapid translational execution.
-
Retatrutide hits phase III endpoints — triple‑agonist shows A1C and weight gains
Eli Lilly announced positive top-line results from Transcend‑T2D‑1: retatrutide—a triple agonist targeting GIP, GLP‑1 and glucagon receptors—met primary and key secondary endpoints in a Phase III trial for type 2 diabetes, delivering up to a 2.0% A1C reduction and mean weight loss of roughly 16.8% (~36.6 lb) at 40 weeks on the highest dose. The company reported safety consistent with GLP‑class agents. Investigators framed the data as a potential step-change in metabolic disease therapy because triple-receptor agonists aim to combine robust glycemic control with profound weight loss. Regulators will review full datasets for safety, tolerability and durability; if confirmed, retatrutide could shift standards for diabetes and obesity management and spur competitive responses across the incretin class. Clarification: Triple-agonists target three hormone receptors (GIP, GLP‑1, glucagon) to simultaneously affect appetite, glucose control and energy expenditure.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.